Previous Close | 75.05 |
Open | 76.18 |
Bid | 81.00 |
Ask | 82.60 |
Strike | 85.00 |
Expire Date | 2025-01-17 |
Day's Range | 75.05 - 76.18 |
Contract Range | N/A |
Volume | |
Open Interest | 7 |
Most readers would already be aware that Johnson & Johnson's (NYSE:JNJ) stock increased significantly by 13% over the...
The Johnson & Johnson filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
Johnson & Johnson (NYSE: JNJ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the first approval of nipocalimab globally for the treatment of people living with generalized myasthenia gravis (gMG).